5995-97-1

Basic information

• Product Name: 4H-1-Benzopyran-4-one, 5,7-bis(acetyloxy)-3-[4-(acetyloxy)phenyl]-
• CAS NO: 5995-97-1
• Molecular Formula: C21H16O8
• Molecular Weight: 396.353
• Mol File: 5995-97-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4H-1-Benzopyran-4-one, 5,7-bis(acetyloxy)-3-[4-(acetyloxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-1-Benzopyran-4-one, 5,7-bis(acetyloxy)-3-[4-(acetyloxy)phenyl]-(5995-97-1)
• EPA Substance Registry System: 4H-1-Benzopyran-4-one, 5,7-bis(acetyloxy)-3-[4-(acetyloxy)phenyl]-(5995-97-1)

Safety Data

• Hazardous Substances Data: 5995-97-1(Hazardous Substances Data)

Upstream product

• 152-95-4 sophoricoside 
• 108-24-7 acetic anhydride 
• 446-72-0 5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-on 

Downstream Products

• 100409-92-5 5-O-methylgenistein diacetate 
• 1610737-96-6 5-(benzyloxy)-3-(4-(benzyloxy)phenyl)-7-morpholino-4H-chromen-4-one 
• 1610737-92-2 5-(benzyloxy)-3-(4-(benzyloxy)phenyl)-4-oxo-4H-chromen-7-yl-4-methylbenzenesulfonate 
• 251985-66-7 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl-4-methylbenzenesulfonate 
• 1610737-86-4 4-(5-acetoxy-4-oxo-7-(tosyloxy)-4H-chromen-3-yl)phenyl acetate 
• 1610737-81-9 4-(5-acetoxy-7-(tert-butoxy)-4-oxo-4H-chromen-3-yl)phenyl acetate 
• 1610737-53-5 4-(5-acetoxy-7-((4-fluorobenzyl)oxy)-4-oxo-4H-chromen-3-yl)phenyl acetate 
• 1610737-75-1 5-hydroxy-3-(4-hydroxyphenyl)-7-morpholino-4H-chromen-4-one 
• 1610737-64-8 7-(tert-butoxy)-5-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one 
• 1093389-85-5 7-((4-fluorobenzyl)oxy)-5-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one 
• 23050-36-4 4-(5-acetoxy-7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl acetate 
• 4569-98-6 7-hydroxy-3-(4-hydroxy-phenyl)-5-methoxy-chromen-4-one 

Relevant articles and documents

-

-

Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75

HIV integrase (IN) is an essential enzyme for the viral replication. Currently, three IN inhibitors have been approved for treating HIV-1 infection. All three drugs selectively inhibit the strand transfer reaction by chelating a divalent metal ion in the

Dietary phytoestrogens and their synthetic structural analogues as calcium channel blockers in human platelets.

Phytoestrogens have been shown to inhibit platelet activation by blocking platelet calcium channels. This study examined the effect of several synthetic derivatives of trans-resveratrol, genistein, and daidzein on platelet free intracellular calcium ([Ca2+]i) elevation in thrombin-activated platelets and the possible mechanisms of this inhibitory effect. Studies were conducted on fresh human platelets from healthy volunteers. The fluorescent dye fura-2 was used to monitor [Ca2+]i in platelets. At 10 microM-resveratrol, triacetyl-trans-resveratrol, and trimethoxy-trans-resveratrol produced, respectively, 57 +/- 4%, 40 +/- 4%, and 21 +/- 1% inhibition; genistein, acetylgenistein, and dihydrogenistein produced 51 +/- 10%, 26 +/- 7%, and 16 +/- 2% inhibition, respectively; daidzein and diacetyldaidzein produced 56 +/- 5% and 45 +/- 10% inhibition of thrombin-induced [Ca2+]i elevation. The inhibitory effect was immediate and appeared to directly affect the calcium influx channels. Phytoestrogen action on [Ca2+]i did not cause alteration in nitric oxide signaling. Tyrosine phosphorylation was not involved in the inhibition of [Ca2+]i elevation by phytoestrogens, because the percent inhibition produced by the tyrosine kinase inhibitor genistein and its inactive analogue daidzein on thrombin-induced and thapsigargin-induced [Ca2+]i elevation was not significantly different for either compound at any concentration tested. Structure-activity relationship studies on this limited set of compounds reveal the requirements for the stilbene pharmacophore for the calcium-blocking activity.